Microsoft word - 201302-ffs-wfi_o.doc

> February 2013
Seeks to generate income and capital growth on a rolling 12 month basis from a diversified portfolio of fixed income securities. Performance summary
Performance – as at 28 February 2013
> The Fund outperformed its benchmark in February primarily Inception Date: 13 Jan 1995
due to its credit exposure as spreads tightened modestly Performance benchmark: UBS Composite Bond (All Maturities) Index
over the month and risk appetite remained firm. Management costs: 0.255%
> We continue to hold a short duration position in the Fund as %
we have been positioned for an improving global economy. > While the Fund remains overweight credit, we have marginally reduced this exposure given the strong fall in credit spreads over the last six months. Investment approach
For our active bond portfolios, we identify value and manage risk through an investment approach that combines interest rate Past performance is not a reliable indicator of future performance. and credit-specific research. This approach includes three key elements: interest rate process - combines a robust quantitative Performance is annualised for periods greater than one year. framework with market analysis to develop strategies in Total returns are calculated using the unit price which uses the net asset values for duration, curve and international interest rate spreads; credit the relevant month end. This price may differ from the actual unit price for an investor applying for or redeeming an investment. Actual unit prices will be confirmed investment style - combines a top-down approach with bottom- following any transaction by an investor. Returns quoted are before tax, after Class up credit analysis; and risk management - we manage risk at a 'O' fees and costs, and assume all distributions are reinvested. fund level by monitoring and controlling three key sources of bond risk/return - credit exposure, duration and yield curve risk. For more information visit
Asset allocation
$10,000,000 invested since inception
February, although the Reserve Bank mildly downgraded its 2013 growth forecast to 2.5% citing the “peak” in mining investment, The AMP Capital Core Plus Strategies Fund (the Fund) fiscal consolidation and the “high” Australian dollar. Australian outperformed its benchmark in February (on a before tax, after economic data released over the month was soft, with weakness fees basis). Most value add came from the Fund’s credit and in retail sales, employment data and business confidence, while currency positions, while the rates positioning weighed on returns. All of the underlying portfolios within the Fund outperformed their benchmarks over the month. Towards month-end, markets were unsettled by the inconclusive Italian election result which led to concerns about Italy’s political The AMP Capital Corporate Bond Fund’s exposure to BBB-rated stability. The election was seen as an emphatic rejection of the credit was again the better performer, with allocations across austerity measures imposed by the Monti government and a risk utilities the standout contributors to returns. Exposures to real to the European Central Bank’s Outright Monetary Transactions estate and industrials also performed well. At the security level, support which had alleviated a significant amount of systemic risk the main contributors to performance were active overweight positions in corporate names such as BAA Funding (Heathrow), DBNGP Finance and SPI Electricity & Gas. Solid performance In the US, economic data maintained positive momentum, was also seen across residential mortgage-backed securities although the focus over the month was on the looming budget sequester involving spending cuts. These commenced at month- exposures, with the better performers including Medallion Trust end and will likely result in another 0.5% of gross domestic product in terms of US fiscal tightening this year, but are not The AMP Capital Credit Strategies Fund’s credit derivative expected to pose a major threat to US growth. exposures added value over the month, particularly within the financials exposures where a few good pair trades with a decompression bias (BNP versus ING and Standard Chartered Markets have enjoyed a strong run in recent months, though we versus Deutsche Bank, both in senior 5-year) added to feel there is some risk of a small pullback from here as investor performance. Corporate strategies saw mixed performance, with positioning feels extended and risk factors are starting to re- gains in technology (Xerox) offset by losses in energy (Dominion, emerge. We are watching political developments in Europe and the US with interest as we see the potential for changes in In terms of the AMP Capital Macro Strategies Fund, bond yields investor sentiment here feeding through to the Australian market. tracked in a range through February before the unexpected Italian Macroeconomic data in the US has slowed, affected in some election late in the month resulted in a hung parliament. This took cases by the level of uncertainty regarding the fiscal cliff and financial markets by surprise and resulted in a short pull-back in sequester. Meanwhile, data across Asia has been improving risk sentiment with bond yields falling into month-end. As a result, particularly in manufacturing, with investors focusing on the recent our rates strategy made a modest loss for the month. However, improvement in Chinese data. Europe, however, is likely to we had shifted our foreign exchange positions to be more remain in recession in 2013 as the impacts of fiscal austerity defensive in nature. We favoured being short euro and British measures and bank deleveraging negatively impact upon the real pound versus the US dollar. We also took profit and reduced our economy and as the inherent imbalances between Germany and prior long positions in risk-correlated currency pairs. This acted as the rest of the Eurozone continue to play out. a partial hedge to our interest rate positions given the rising risks in Europe. Our foreign exchange positions contributed positively to performance and more than offset the loss from our interest rate strategy. Market commentary
In Australia, the official cash rate remained steady at 3% in
Investment objective
To provide a total return (income and capital growth) after costs and before tax, above the Fund's performance benchmark on a rolling
12 month basis.
Investors should consider the current product disclosure statement (PDS) available from AMP Capital Investors Limited (ABN 59001 777 591) (AFSL 232497) (AMP Capital) for the AMP CAPITAL CORE PLUS STRATEGIES FUND - WHOLESALE (Fund) unit class before making any decision regarding the Fund. The PDS contains important information about investing in the Fund and it’s important investors read the PDS before making a decision about whether to acquire, continue to hold or dispose of units in the Fund. Neither AMP Capital, nor any other company in the AMP Group, guarantees the repayment of capital or the performance of the product or any particular rate of return. Past performance is not a reliable indicator of future performance. AMP Capital makes no representation or warranty as to the accuracy or completeness of any statement in this fact sheet including any forecasts. This fact sheet has been prepared for the purpose of providing general information, without taking account of any particular investor's objectives, financial situation, or needs. An investor should, before making any investment decisions, consider the appropriateness of the information in this fact sheet, and seek professional advice, having regard to the investor's objectives, financial situation, and needs. For more information
Or your institutional sales executive


Microsoft word - sgrq-c manual 2008.doc

ST GEORGE’S RESPIRATORY QUESTIONNAIRE FOR COPD PATIENTS (SGRQ-C) Professor Paul Jones Division of Cardiac and Vascular Science St George’s, University of London London SW17 0RE Tel +44 (0) 208 725 5371Fax +44 (0) 208 725 5955 CONTENTS 1. THE SGRQ The SGRQ-C was developed from the SGRQ which was designed to measure healthimpairment in patients with asthma and COPD. The

Umhs approved clinical care guideline - how to quit smoking

UMHS Approved Clinical Care Guideline - How to Quit Smoking How to Quit Smoking Patient Education Handout associated with UMHS Clinical Care Guideline This information is not a tool for self-diagnosis or a substitute for medical treatment. You should speak to be seen if you have questions or concerns about this information or your medical condition. Translations available in: , Ho

Copyright © 2010-2014 Online pdf catalog